INFINITY PHARMACEUTICALS, INC. Form 8-K April 09, 2013

UNITED STATES SECURITIES AND EXCHANGE COMMISSION

WASHINGTON, D.C. 20549

FORM 8-K

CURRENT REPORT

PURSUANT TO SECTION 13 OR 15(d) OF

THE SECURITIES EXCHANGE ACT OF 1934

Date of Report (Date of earliest event reported): April 3, 2013

Infinity Pharmaceuticals, Inc.

(Exact name of registrant as specified in charter)


Delaware (State or other jurisdiction

000-31141 (Commission 33-0655706 (IRS Employer

of incorporation) File Number) Identification No.)

Edgar Filing: INFINITY PHARMACEUTICALS, INC. - Form 8-K

780 Memorial Drive, Cambridge, MA 02139
(Address of principal executive offices) (Zip Code)
Registrant s telephone number, including area code: (617) 453-1000



- " Written communications pursuant to Rule 425 under the Securities Act (17 CFR 230.425)
- " Soliciting material pursuant to Rule 14a-12 under the Exchange Act (17 CFR 240.14a-12)
- " Pre-commencement communications pursuant to Rule 14d-2(b) under the Exchange Act (17 CFR 240.14d-2(b))
- " Pre-commencement communications pursuant to Rule 13e-4(c) under the Exchange Act (17 CFR 240.13e-4(c))

Edgar Filing: INFINITY PHARMACEUTICALS, INC. - Form 8-K

Item 5.02. Departure of Directors or Certain Officers; Election of Directors; Appointment of Certain Officers; Compensatory Arrangements of Certain Officers.

- (b) On April 3, 2013, Christopher M. Lindblom, our Vice President, Accounting and Finance, who also served as our principal accounting officer, informed our company that he will be resigning from his position effective May 3, 2013.
- (c) On April 7, 2013, our board of directors appointed Lawrence E. Bloch, M.D., J.D. as our principal accounting officer effective immediately. Dr. Bloch, age 47, has served as our Executive Vice President, Chief Financial Officer and Chief Business Officer since July 2012. Prior to joining our Company, Dr. Bloch served as chief executive officer of NeurAxon, Inc., a privately-held biopharmaceutical company, from 2007 to 2011. Previously, he served as chief financial officer and chief business officer of NitroMed, Inc., a publicly-held biopharmaceutical company, from 2004 to 2006. From 2000 to 2004, Dr. Bloch served as Chief Financial Officer, and from 1999 to 2002 as vice president of business development, of Applied Molecular Evolution, Inc., a publicly-held biopharmaceutical company. Dr. Bloch began his career as an emergency medicine resident physician at Massachusetts General Hospital and Brigham & Woman s Hospital. He holds a J.D. from Harvard Law School, an M.D. from Harvard Medical School and an M.B.A. from Harvard Business School.

Edgar Filing: INFINITY PHARMACEUTICALS, INC. - Form 8-K

SIGNATURE

Pursuant to the requirements of the Securities Exchange Act of 1934, the Registrant has duly caused this report to be signed on its behalf by the undersigned hereunto duly authorized.

INFINITY PHARMACEUTICALS, INC.

Date: April 9, 2013 By: /s/ Lawrence E. Bloch

Lawrence E. Bloch, M.D., J.D.

EVP, Chief Financial Officer and Chief Business Officer